Skip to main content
SpringerLink
Log in
Book cover

Betreuung drogenabhängiger Schwangerer und ihrer Neugeborenen pp 21–38Cite as

Pharmakologische Aspekte der intrauterinen Drogenexposition und klinische Konsequenzen

  • Chapter

  • 959 Accesses

Zusammenfassung

Ein neonatales Abstinenzsyndrom (NAS) tritt bei etwa 50–90% der Neugeborenen auf, die vorgeburtlich über längere Zeit hinweg Opioiden ausgesetzt waren [15]. Während der letzten Jahre hat sich die Häufi gkeit des NAS deutlich erhöht. In den USA stieg von 2004 bis 2013 die Rate von Neugeborenen, die mit einem NAS auf einer neonatologischen Intensivstation aufgenommen worden waren, von 17 auf 27 pro 1000 Aufnahmen [36]. Parallel dazu nahm die Behandlungsdauer auf der Intensivstation deutlich zu und ebenso der Anteil der Neugeborenen, die eine pharmakologische Th erapie des Abstinenzsyndroms erhielten.

This is a preview of subscription content, log in via an institution.

eBook
USD   19.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   29.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abduljalil K, Furness P, Johnson TN et al. Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. Clin Pharmacokinet 2012; 51: 365–396.

    Article  CAS  PubMed  Google Scholar 

  2. Allegaert K, Vanhaesebrouck S, Verbesselt R et al. In vivo glucuronidation activity of drugs in neonates: extensive interindividual variability despite their young age. Ther Drug Monit 2009; 31: 411–415.

    Article  CAS  PubMed  Google Scholar 

  3. Anand KJ, Anderson BJ, Holford NH et al. Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. Br J Anaesth 2008; 105: 680–689.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Dancis J, Braverman N, Lind J. Plasma protein synthesis in the human fetus and placenta. J Clin Invest 1957; 36: 398–404.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Daood MJ, Tsai C, Ahdab-Barmada M et al. ABC transporter (Pgp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS. Neuropediatrics 2008; 39: 11–18.

    Article  CAS  PubMed  Google Scholar 

  6. de Castro A, Jones HE, Johnson RE et al. Methadone, cocaine, opiates and metabolite dispositions in umbilical cord and correlations to maternal methadone dose and neonatal outcomes. Ther Drug Monit 2011; 33: 443–452.

    Google Scholar 

  7. de Castro A, Jones HE, Johnson RE et al. Maternal methadone dose, placental methadone concentrations, and neonatal outcomes. Clin Chem 2011; 57: 449–458.

    Google Scholar 

  8. Ekström L, Johansson M, Rane A. Tissue distribution and relative gene expression of UDP-Glucuronosyl transferases (2B7, 2B15, 2B17) in the human fetus. Drug Metab Disp 2013; 41: 291–295.

    Article  CAS  PubMed  Google Scholar 

  9. Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet 2005; 44: 661–680.

    Article  CAS  PubMed  Google Scholar 

  10. Fokina VM, Patrikeeva SL, Zharikova L et al. Transplancental transfer and metabolism of buprenorphine in preterm human placenta. Am J Perinatol 2011; 28: 25–32.

    Article  Google Scholar 

  11. Fukuda T, Chidamboran V, Mizuno T et al. OCT1 genetic variants influence the pharmacokinetics of morphine in children. Pharmacogenomics 2013; 14: 1141–1151.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Hakkola J, Pasanen M, Hukkanen J et al. Expression of xenobiotic – metabolizing cytochrome P450 forms in human fullterm placenta. Biochem Pharmacol 1996; 51: 403–411.

    Google Scholar 

  13. Hartley R, Green M, Quinn MW. Development of morphine glucuronidation in premature neonates. Biol Neonate 1994; 66: 1–9.

    Article  CAS  Google Scholar 

  14. Hieronymus TL, Nanovskaya TN, Deshmukh SV et al. Methadone metabolism by early gestational age placentas. Am J Perinatol 2006; 23: 287–294.

    Article  PubMed  Google Scholar 

  15. Hudak ML, Tan RC, The Committee on Drugs, the Commitee on Fetus and Newborn. Neonatal drug withdrawal. Pediatrics 2012; 129: e540–560.

    Google Scholar 

  16. Iqbal M, Audette MC, Petropoulos S. Placental drug transporters and their role in fetal protection. Placenta 2012; 33: 137–142.

    Article  CAS  PubMed  Google Scholar 

  17. Isokerranen N, Thummel KE. Drug metabolism and transport during pregnancy: How does drug disposition change during pregnancy and what are the mechanisms that cause such changes? Drug Metab Disp 2013; 41: 256–262.

    Google Scholar 

  18. Jones HE, Johnson RE, Jasinski DR et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence 2005; 79: 1–10.

    Article  CAS  PubMed  Google Scholar 

  19. Jones HE, Kaltenbach K, Heil SH et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. NEJM 2010; 363: 2320–2331.

    Article  CAS  PubMed  Google Scholar 

  20. Kearns GL, Abdel-Rahman SM, Alander SW et al. Developmental pharmacology – drug disposition, action, and therapy in infants and children. NEJM 2003; 349: 1157–1167.

    Article  CAS  PubMed  Google Scholar 

  21. Knibbe CA, Krekels EH, van den Anker JN et al. Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clin Pharmacokinet 2009; 48: 371–385.

    Article  CAS  PubMed  Google Scholar 

  22. Koren G. Changes in drug disposition in pregnancy and their clinical implications. In: Koren G (ed.): Maternal-fetal toxicology. 2nd ed. New York: Marcel Dekker, 1994, pp 1–13.

    Google Scholar 

  23. Lam J, Koren G. P-glycoprotein in the developing brain: A review of the effects of ontogeny on the safety of opioids in neonates. Ther Drug Monit 2014; 36: 699–705.

    Google Scholar 

  24. Lejeune C, Simmat-Durand L, Gouraier L et al. Prospective multicenter observational study of 260 infants born to 259 opiatedependent mothers on methadone or high-dose buprenorphine substitution. Drug and Alcohol Dependence 2006; 82: 250–257.

    Article  CAS  PubMed  Google Scholar 

  25. Lewis T, Dinh J, Leeder JS. Genetic determinants of fetal opiate exposure and risk of neonatal abstinence syndrome: knowledge deficites and prospects for future research. Clin Pharmacol Ther 2015; 98: 309–320.

    Article  CAS  Google Scholar 

  26. Loebstein R, Lalkin A, Koren G. Pharmacokinetic changes during pregnancy and their relevance. Clin Pharmacokinet 1997; 33: 328–343.

    Google Scholar 

  27. Malek A, Obrist C, Wentzinger S et al. The impact of cocaine and heroin on the placental transfer of methadone. Reprod Biol Endocrinol 2009; 7: 61.

    Article  CAS  PubMed  Google Scholar 

  28. Matic M, van den Bosch GE, de Wildt SN et al. Genetic variants associated with thermal pain sensitivity in a pediatric population. Pain 2016; 157: 2476–2482.

    Article  PubMed  Google Scholar 

  29. Miller RK, Kostalka TR, Brent RL. The transport of molecules across placental membranes. In: Poste G, Nicolson GL (eds.): The cell surface in animal embryogenesis and development. Amsterdam, New York, Oxford: North-Holland Publishing, 1976, pp 145–223.

    Google Scholar 

  30. Mooij MG, Nies AT, Knibbe CA et al. Development of human membrane transporters: drug disposition and pharmacogenetics. Clin Pharmacokinet 2016; 55: 507–524.

    Article  CAS  PubMed Central  Google Scholar 

  31. Nanovskaya TN, Deshmukh SV, Nekhayeva IA et al. Methadone metabolism by human placenta. Biochem Pharmacol 2004; 68: 583–591.

    Article  CAS  PubMed  Google Scholar 

  32. Nekhyeva IA, Nanovskaya TN, Hankins GO et al. Role of human placental efflux transporter P-glycoprotein in the transfer of buprenorphine, levo-alpha-acetyl-methadol, and paclitaxel. Am J Perinatol 2006; 23: 423–430.

    Google Scholar 

  33. Pasanen M, Pelkonen O. The expression and environmental regulation of P450 enzymes in human placenta. Crit Rev Toxicol 1994; 24: 211–229.

    Article  CAS  PubMed  Google Scholar 

  34. Seligman NS, Almario CV, Hayes EJ et al. Relationship between maternal methadone dose at delivery and neonatal abstinence syndrome. J Pediatr 2010; 157: 428–433.

    Article  CAS  Google Scholar 

  35. Sun M, Kingdom J, Baczyk D et al. Expression of the multidrug resistance P-glycoprotein (ABCB1 glycoprotein) in human placenta decreases with advancing gestation. Placenta 2006; 27: 602–609.

    Article  CAS  PubMed  Google Scholar 

  36. Tolia VN, Patrick SW, Bennett MM et al. Increasing incidence of the neonatal abstinence syndrome in U. S. Neonatal ICUs. NEJM 2015; 372: 2118–2126.

    Article  PubMed  Google Scholar 

  37. Tracy TS, Venkataramanan R, Glover DD et al. Temporal changes in drug metabolism (CYP1A2, CYP206 and CYP3A activity) during pregnancy. Am J Obstet Gynecol 2005; 192: 633–639.

    Article  CAS  PubMed  Google Scholar 

  38. Tzvetkov MV, dos Santos Pereira, Meineke I et al. Morphine is a substrate of the organic cation transporter OCT1 and polymorphism in OCT1 gene affect morphine pharmacokinetics after codeine administration. Biochemical Pharmacology 2013; 86: 666–678.

    Article  CAS  PubMed  Google Scholar 

  39. Wachman EM, Hayes MJ, Brown MS et al. Association of OPRM1 and COMT single-nucleotide polymorphism with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA 2013; 309: 1821–1827.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Kinder- und Jugendmedizin, Neonatologie und pädiatrische Intensivmedizin, Universitätsklinikum Köln, Kerpener Straße 62, 50937, Köln, Deutschland

    Bernhard Roth

Authors
  1. Bernhard Roth
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Kinder- und Jugendheilkunde, Medizinische Universität Wien, Wien, Austria

    Ludwig Gortner

  2. Klinik für Geburtsmedizin, Berlin, Deutschland

    Joachim W. Dudenhausen

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Medizin Verlag GmbH

About this chapter

Cite this chapter

Roth, B. (2017). Pharmakologische Aspekte der intrauterinen Drogenexposition und klinische Konsequenzen. In: Gortner, L., Dudenhausen, J.W. (eds) Betreuung drogenabhängiger Schwangerer und ihrer Neugeborenen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-89935-307-5_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-89935-307-5_2

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-89935-306-8

  • Online ISBN: 978-3-89935-307-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation